Skip to main content
Premium Trial:

Request an Annual Quote

Prime Health Services to Cover GenomeDx's Prostate Cancer Risk Test

NEW YORK (GenomeWeb) – GenomeDx today announced an agreement with Prime Health Services providing coverage of GenomeDx's prostate cancer test.

Under the terms of the deal, the test, called Decipher, will be covered by Prime Health for patients whose physicians order it. Prime Health's network includes 9 million covered lives and brings the total number of covered lives for Decipher to about 120 million, GenomeDx said.

Decipher uses whole-genome analysis to profile RNA expression signatures to measure the aggressiveness of prostate cancer in patients who have had a prostatectomy. The test provides information that is distinct from PSA information and other clinical risk factors, San Diego-based GenomeDx said.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.